Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management
Authors: Pabón‐Carrasco Manuel , Keco‐Huerga Alma , Castro‐Fernández Manuel , Saracino Ilaria Maria , Fiorini Giulia , Vaira Dino , Pérez‐Aísa Ángeles , Tepes Bojan , Jonaitis Laimas , Voynovan Irina , Lucendo Alfredo J. , Lanas Ángel , Martínez‐Domínguez Samuel J. , Almajano Enrique Alfaro , Rodrigo Luis , Vologzanina Ludmila , Brglez Jurecic Natasa , Denkovski Maja , Bujanda Luis , Abdulkhakov Rustam A. , Huguet Jose M. , Fernández‐Salazar Luis , Alcaide Noelia , Velayos Benito , Silkanovna Sarsenbaeva Aiman , Zaytsev Oleg , Ilchishina Tatiana , Barrio Jesús , Bakulin Igor , Perona Monica , Alekseenko Sergey , Romano Marco , Gravina Antonietta G. , Núñez Óscar , Gómez Rodríguez Blas José , Ledro‐Cano Diego , Pellicano Rinaldo , Bogomolov Pavel , Domínguez‐Cajal Manuel , Almela Pedro , Gomez‐Camarero Judith , Bordin Dmitry S. , Gasbarrini Antonio , Kupčinskas Juozas , Cano‐Català Anna , Moreira Leticia , Nyssen Olga P. , Mégraud Francis , O’Morain Colm , Gisbert Javier P. ,   the Hp‐EuReg Investigators
Published: December 2023

Background

Management of Helicobacter pylori (H. pylori) infection requires co‐treatment with proton pump inhibitors (PPIs) and the use of antibiotics to achieve successful eradication.

Aim

To evaluate the role of dosage of PPIs and the duration of therapy in the effectiveness of H. pylori eradication treatments based on the ‘European Registry on Helicobacter pylori management’ (Hp‐EuReg).

Methods

Hp‐EuReg is a multicentre, prospective, non‐interventionist, international registry on the routine clinical practice of H. pylori management by European gastroenterologists. All infected adult patients were systematically registered from 2013 to 2022.

Results

Overall, 36,579 patients from five countries with more than 1000 patients were analysed. Optimal (≥90%) first‐line‐modified intention‐to‐treat effectiveness was achieved with the following treatments: (1) 14‐day therapies with clarithromycin‐amoxicillin‐bismuth and metronidazole‐tetracycline‐bismuth, both independently of the PPI dose prescribed; (2) All 10‐day (except 10‐day standard triple therapy) and 14‐day therapies with high‐dose PPIs; and (3) 10‐day quadruple therapies with clarithromycin‐amoxicillin‐bismuth, metronidazole‐tetracycline‐bismuth, and clarithromycin‐amoxicillin‐metronidazole (sequential), all with standard‐dose PPIs. In first‐line treatment, optimal effectiveness was obtained with high‐dose PPIs in all 14‐day treatments, in 10‐ and 14‐day bismuth quadruple therapies and in 10‐day sequential with standard‐dose PPIs. Optimal second‐line effectiveness was achieved with (1) metronidazole‐tetracycline‐bismuth quadruple therapy for 14‐ and 10 days with standard and high‐dose PPIs, respectively; and (2) levofloxacin‐amoxicillin triple therapy for 14 days with high‐dose PPIs. None of the 7‐day therapies in both treatment lines achieved optimal effectiveness.

Conclusions

We recommend, in first‐line treatment, the use of high‐dose PPIs in 14‐day triple therapy and in 10‐or 14‐day quadruple concomitant therapy in first‐line treatment, while standard‐dose PPIs would be sufficient in 10‐day bismuth quadruple therapies. On the other hand, in second‐line treatment, high‐dose PPIs would be more beneficial in 14‐day triple therapy with levofloxacin and amoxicillin or in 10‐day bismuth quadruple therapy either as a three‐in‐one single capsule or in the traditional scheme.